Serum-Derived Bovine Immunoglobulin Promotes Barrier Integrity and Lowers Inflammation for 24 Human Adults Ex Vivo

• Published in: Nutrients Vol. 16; no. 11; p. 1585
• Main Authors: Van den Abbeele, Pieter, Kunkler, Charlotte N., Poppe, Jonas, Rose, Alexis, van Hengel, Ingmar A. J., Baudot, Aurélien, Warner, Christopher D.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23.05.2024; MDPI
• Subjects: Adult; Animals; Caco-2 Cells; Care and treatment; Cattle; Clinical trials; Colon - drug effects; Colon - metabolism; Colon - microbiology; Colorectal diseases; Development and progression; Fatty Acids, Volatile - metabolism; Feces; Female; Fermentation; Gastrointestinal diseases; Gastrointestinal Microbiome - drug effects; Gastrointestinal system; Health aspects; Homeostasis; Humans; Immunoglobulins; Inflammation; Intestinal Mucosa - drug effects; Intestinal Mucosa - metabolism; Intestinal Mucosa - microbiology; Inulin - pharmacology; Male; Metabolites; Microbiota; Microbiota (Symbiotic organisms); Middle Aged; Physiological aspects; Prebiotics; Proteins; THP-1 Cells; Belgium; Anaerostipes hadrus; branched-chain fatty acids (bCFA); Coprococcus comes; short-chain fatty acid (SCFA); Bacteroides vulgatus; Bifidobacterium adolescentis; systemic intestinal fermentation research (SIFR); Faecalibacterium prausnitzii; lipopolysaccharides (LPS); linear mixed model
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu16111585

Serum-derived bovine immunoglobulin (SBI) prevents translocation and inflammation via direct binding of microbial components. Recently, SBI also displayed potential benefits through gut microbiome modulation. To confirm and expand upon these preliminary findings, SBI digestion and colonic fermentation were investigated using the clinically predictive ex vivo SIFR® technology (for 24 human adults) that was, for the first time, combined with host cells (epithelial/immune (Caco-2/THP-1) cells). SBI (human equivalent dose (HED) = 2 and 5 g/day) and the reference prebiotic inulin (IN; HED = 2 g/day) significantly promoted gut barrier integrity and did so more profoundly than a dietary protein (DP), especially upon LPS-induced inflammation. SBI also specifically lowered inflammatory markers (TNF-α and CXCL10). SBI and IN both enhanced SCFA (acetate/propionate/butyrate) via specific gut microbes, while SBI specifically stimulated valerate/bCFA and indole-3-propionic acid (health-promoting tryptophan metabolite). Finally, owing to the high-powered cohort (n = 24), treatment effects could be stratified based on initial microbiota composition: IN exclusively stimulated (acetate/non-gas producing) Bifidobacteriaceae for subjects classifying as Bacteroides/Firmicutes-enterotype donors, coinciding with high acetate/low gas production and thus likely better tolerability of IN. Altogether, this study strongly suggests gut microbiome modulation as a mechanism by which SBI promotes health. Moreover, the SIFR® technology was shown to be a powerful tool to stratify treatment responses and support future personalized nutrition approaches.